Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

about

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

Item

http://www.wikidata.org/entity/Q55055819

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@en

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@nl

type

Item

label

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@en

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@nl

prefLabel

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@en

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@nl

P1476

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

@en

P2093

Francesco Facchinetti

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib resistance: implications for therapeutic strategies

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

P304

S103-S106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TLCR.2018.02.04

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luc Friboulet

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29782561

http://www.w3.org/2001/XMLSchema#string

P932

5943229

http://www.w3.org/2001/XMLSchema#string